Last reviewed · How we verify
Patent clopidogrel
Patent clopidogrel is a P2Y12 receptor antagonist / Thienopyridine antiplatelet agent Small molecule drug developed by Hospital Central San Luis Potosi, Mexico. It is currently FDA-approved for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction), ST-elevation myocardial infarction, Peripheral arterial disease. Also known as: Plavix.
Clopidogrel inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor on platelets.
Clopidogrel is a small molecule medication used to treat various conditions, including heart attack, stroke, and ischemic events, as well as chronic kidney disease. It is typically administered at a dose of 75mg.
At a glance
| Generic name | Patent clopidogrel |
|---|---|
| Also known as | Plavix |
| Sponsor | Hospital Central San Luis Potosi, Mexico |
| Drug class | P2Y12 receptor antagonist / Thienopyridine antiplatelet agent |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a thienopyridine prodrug that requires hepatic metabolism to its active form. The active metabolite irreversibly binds to the P2Y12 receptor on platelet surfaces, preventing ADP-induced platelet activation and aggregation. This antiplatelet effect reduces thrombotic events in patients at risk of cardiovascular complications.
Approved indications
- Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
- ST-elevation myocardial infarction
- Peripheral arterial disease
- Ischemic stroke or transient ischemic attack
- Secondary prevention of atherothrombotic events
Common side effects
- Bleeding
- Dyspepsia
- Diarrhea
- Rash
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years (PHASE3)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction. (PHASE3)
- Adjuvant Clopidogrel in Staphylococcus Aureus Bacteremia (PHASE2)
- PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy (NA)
- Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Patent clopidogrel CI brief — competitive landscape report
- Patent clopidogrel updates RSS · CI watch RSS
- Hospital Central San Luis Potosi, Mexico portfolio CI
Frequently asked questions about Patent clopidogrel
What is Patent clopidogrel?
How does Patent clopidogrel work?
What is Patent clopidogrel used for?
Who makes Patent clopidogrel?
Is Patent clopidogrel also known as anything else?
What drug class is Patent clopidogrel in?
What development phase is Patent clopidogrel in?
What are the side effects of Patent clopidogrel?
What does Patent clopidogrel target?
Related
- Drug class: All P2Y12 receptor antagonist / Thienopyridine antiplatelet agent drugs
- Target: All drugs targeting P2Y12 receptor
- Manufacturer: Hospital Central San Luis Potosi, Mexico — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Acute coronary syndrome (unstable angina and non-ST elevation myocardial infarction)
- Indication: Drugs for ST-elevation myocardial infarction
- Indication: Drugs for Peripheral arterial disease
- Also known as: Plavix
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing